Novartis Showcases Rhapsido Data at EAACI 2026
BASEL, Switzerland, June 8, 2026 Novartis announced the presentation of data from 10 scientific abstracts at the European Academy...
phase III trial
Advertisement
Zealand Pharma Highlights Positive Phase III Survodutide Results in Obesity
COPENHAGEN, Denmark, June 7, 2026 Zealand Pharma A/S announced that its partner Boehringer Ingelheim presented detailed results from the...
Antengene Expands Oncology Pipeline With Phase III ATG-022 Gastric Cancer Trial
SHANGHAI and HONG KONG, China, May 28, 2026 Antengene has announced a major clinical development milestone after receiving endorsement...
InnoCare Wins China NDA Acceptance for Orelabrutinib in ITP
BEIJING — May 28, 2026 InnoCare Pharma announced that China’s Center for Drug Evaluation (CDE) under the National Medical...
Innovent IBI363 Shows Strong Survival in NSCLC
SAN FRANCISCO and SUZHOU, China, May 21, 2026 Innovent Biologics, Inc. announced updated long-term clinical data from the Phase...
Advertisements
GSK Expands Arexvy Approval for At-Risk Adults
LONDON, United Kingdom, May 20, 2026 GSK has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved...
Leads Biolabs Wins Phase III Approval for Opamtistomig in Advanced EP-NEC
NANJING, China, May 18, 2026 Leads Biolabs announced that its proprietary PD-L1/4-1BB bispecific antibody Opamtistomig (LBL-024) has received approval...
AstraZeneca’s FASENRA Wins FDA Approval for HES
WILMINGTON, Del., May 14, 2026 AstraZeneca announced that the U.S. Food and Drug Administration has approved FASENRA® (benralizumab) for...
Meiji Seika Reports Positive Phase III Nacubactam Data
TOKYO, Japan, May 15, 2026 Meiji Seika Pharma Co., Ltd. announced that positive results from the global Phase III...
AstraZeneca Reports Positive Phase III Results for Eneboparatide in HypoPT
PRAGUE, Czech Republic, May 12, 2026 AstraZeneca and Alexion announced positive Phase III clinical trial results for eneboparatide (AZP-3601),...
Advertisement
